Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Big Data Institute (BDI) have recently announced new research alliances with Novartis and Sensyne Health

Outside of the big data institute

The Big Data Institute (BDI) have recently announced two new research alliances:

  1. A five-year collaboration with Novartis to establish a world-leading research alliance that will improve drug development by making it more efficient and more targeted. Using artificial intelligence (AI) and advanced analytics, the partners expect to transform how ultra large and multiple datasets are analysed, combined and interpreted to identify early predictors of patient responses to treatments for inflammatory diseases, such as multiple sclerosis (MS) and psoriasis. Read more (BDI website)
  2. A three year alliance with Sensyne Health to advance the analysis and interpretation of NHS datasets. These datasets, in chronic kidney disease and cardiovascular disease, will be analysed using clinical artificial intelligence that will be used to improve care and accelerate the discovery and development of new medicines. Read more (BDI website)

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.